Adaptive Bayesian compound designs for dose finding studies

Journal of Statistical Planning and Inference

Volumn 142, Issue 6, 2012, Pages 1480-1492

  McGree, J M ^a   Drovandi, C C ^a   Thompson, M H ^a   Eccleston, J A ^b   Duffull, S B ^c   Mengersen, K ^a   Pettitt, A N ^a   Goggin, T ^d  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Adaptive design; Compound utility; Importance sampling; Markov chain Monte Carlo; Optimal design; Safety; Utility functions

Indexed keywords

EID: 84857140510     PISSN: 03783758     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jspi.2011.12.029     Document Type: Article

References (30)

1. Babb J., Rogatko A., Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998, 17:1103-1400.
2. Biedermann S., Dette H., Zhu W. Compound optimal designs for percentile estimation in dose-response models with restricted design intervals. Journal of Statistical Planning and Inference 2007, 137:3838-3847.
3. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005, 352:1092-1102.
4. Chaudhuri P., Mykland P.A. Nonlinear experiments: optimal design and inference based on likelihood. Journal of the American Statistical Association 1993, 88:538-546.
5. Chevret S. Statistical Methods for Dose-Finding Experiments 2006, Wiley Statistics in Practice. John Wiley & Sons, England.
6. Dixon W.J., Mood A.M. A method for obtaining and analysing sensitivity data. Journal of the American Statistical Association 1948, 43:109-126.
7. Dragalin V., Fedorov V.V., Wu Y. Adaptive designs for selecting drug combinations based on efficacy-toxicity response. Journal of Statistical Planning and Inference 2008, 138:352-373.
8. Dror H.A., Steinberg D.M. Sequential experimental designs for generalized linear models. Journal of the American Statistical Association 2008, 103:288-298.
9. Goodman S.N., Zahurak M.L., Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995, 14:1149-1161.
10. Haines L.M., Perevozskaya I., Rosenberger W.F. Bayesian optimal designs for phase I clinical trials. Biometrics 2003, 59:591-600.
11. Korn E., Midthune D., Chen T., Rubinstein L., Christian M.C., Simon R. A comparison of two phase I trial designs. Statistics in Medicine 1994, 13:1799-1806.
12. McCullagh P., Nelder J.A. Generalized Linear Models 1989, Chapman and Hall. second ed.
13. McGree J.M., Eccleston J.A., Duffull S.B. Compound optimal design criteria for nonlinear models. Journal of Biopharmaceutical Statistics 2008, 18:646-661.
14. Müller P., Berry D.A., Grieve A.P., Smith M., Krams M. Simulation-based sequential Bayesian design. Journal of Statistical Planning and Inference 2007, 137:3140-3150.
15. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990, 46:33-48.
16. O'Quigley J., Reiner E. A stopping rule for the continual reassessment method. Biometrika 1998, 85:741-748.
17. Ratain M., Mick R., Schilsky R.L., Siegler M. Statistical and ethical issues in the design and conduct of phase i and ii clinical trials of new anti-cancer agents. Journal of the National Cancer Institute 1993, 85:1637-1643.
18. Robbins H., Monro S. A stochastic approximation method. Annals of Mathematical Statistics 1951, 29:400-407.
19. Rosenberger W.F., Haines L.M. Competing designs for phase I clinical trials: a review. Statistics in Medicine 2002, 21:2757-2770.
20. Thall P.F., Nguyen H.Q., Estey E.H. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics 2008, 64:1126-1136.
21. Tierney L. Markov chains for exploring posterior distributions. Annals of Statistics 1994, 22:1701-1762. (with discussion and a rejoinder by the author).
22. Tsutakawa R.K. Selection of dose levels for estimating a percentage point of a logistic quantal response curve. Applied Statistics 1980, 29:25-33.
23. Whitehead J., Brunier H. Bayesian decision procedures for dose determining experiments. Statistics in Medicine 1995, 14:885-893.
24. Whitehead J., Williamson D. Bayesian decision procedures based on logistic regression models for dose-finding studies. Journal of Biopharmaceutical Statistics 1998, 8:445-467.
25. Whitehead J., Zhou Y., Patterson S., Webber D., Francis S. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2001, 2:47-61.
26. Whitehead J., Zhou Y., Mander A., Ritchie S., Sabin A., Wright A. An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics in Medicine 2006, 25:433-445.
27. Whitehead J., Zhou Y., Stevens J., Blakey G., Price J., Leadbetter J. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in Medicine 2006, 25:37-53.
28. Zhou Y., Whitehead J. Practical implementation of Bayesian dose escalation procedure. Drug Information Journal 2003, 37:45-59.
29. Zhou Y., Whitehead J., Bonvini E., Stevens J.W. Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics 2006, 5:125-133.
30. Zhou Y., Whitehead J., Korhonen P., Mustonen M. Implementation of a Bayesian design in a dose-escalation study of an experimental agent in healthy volunteers. Biometrics 2008, 64:299-308.